Search

Your search keyword '"Respiratory system agents -- Health aspects"' showing total 498 results
Start Over Descriptor "Respiratory system agents -- Health aspects"
498 results on '"Respiratory system agents -- Health aspects"'

201. An epidemiological study of Henoch-Schonlein purpura: Kay Penny and colleagues suggest nurses need to be aware of the signs and symptoms, and treatments that are available to better understand this disease

Author

Penny, Kay, Fleming, Michael, Kazmierczak, Denise, and Thomas, Angela

Subjects
American College of Rheumatology, Usage, Surveys, Health aspects, Software quality, Hospitals -- United Kingdom -- Health aspects, Analgesics -- Usage -- Health aspects, Pediatric diseases -- Health aspects, Purpura -- Health aspects, Nursing -- Health aspects, Medical research -- Health aspects, Emergency medicine -- Health aspects, Epidemiology -- Health aspects, Glucocorticoids -- Health aspects, Kidney diseases -- Health aspects, Software -- Usage -- Health aspects, Lupus -- Health aspects, Evidence-based medicine -- Health aspects, Respiratory system agents -- Health aspects, Heat shock proteins -- Health aspects, Corticosteroid drugs -- Usage -- Health aspects, Nurses -- Surveys -- Health aspects, Respiratory agents -- Health aspects, Children -- Diseases, Medicine, Experimental -- Health aspects, Corticosteroids -- Usage -- Health aspects, Purpura (Pathology) -- Health aspects
Abstract

Aim To describe the incidence of hospital admission among children in the Scottish population for Henoch-Schonlein purpura (HSP). Method The annual, quarterly and monthly incidences of HSP were derived from [...]

Published
2010

202. Epidemiology of Cryptococcus gattii, British Columbia, Canada, 1999-2007

Author

Galanis, Eleni and MacDougall, Laura

Subjects
Development and progression, Health aspects, Mycoses -- Development and progression -- Health aspects, Respiratory system agents -- Health aspects, Medical research -- Health aspects, HIV -- Development and progression -- Health aspects, Epidemiology -- Health aspects, HIV (Viruses) -- Development and progression -- Health aspects, Medicine, Experimental -- Health aspects, Respiratory agents -- Health aspects
Abstract

Cryptoccocus gattii is an environmental fungus that emerged in a temperate climate on Vancouver Island, British Columbia, Canada, in 1999, causing an outbreak affecting humans and animals (1,2). Previously, C. [...]

Published
2010
Full Text
View/download PDF

204. Long-term, ambulatory and short-burst oxygen therapy in the community

Author

D, Lynes and C, Kelly

Subjects
Care and treatment, Health aspects, Chronic diseases -- Care and treatment -- Health aspects, Obesity -- Care and treatment -- Health aspects, Hypertension -- Care and treatment -- Health aspects, Professional development -- Health aspects, Practice guidelines (Medicine) -- Health aspects, Explosions -- Health aspects, Chronic obstructive lung disease -- Care and treatment -- Health aspects, Respiratory system agents -- Health aspects, Medical research -- Health aspects, Cardiac patients -- Care and treatment -- Health aspects, Nurses -- Health aspects, Oximetry -- Health aspects, Respiratory agents -- Health aspects, Medicine, Experimental -- Health aspects, Lung diseases, Obstructive -- Care and treatment -- Health aspects
Abstract

This article examines assessment and management strategies for all categories of domiciliary oxygen therapy for adult patients. It highlights the evidence underpinning each category, and enables dissemination of good practice [...]

Published
2009

205. Inhaled protein treatment 'reduces the odds of developing severe Covid'; Results of a clinical trial suggest patients who received the drug were more than twice as likely to recover

Subjects
Clinical trials -- Health aspects, Interferon beta -- Health aspects, Hospital patients -- Health aspects, Biological response modifiers -- Health aspects, Viral antigens -- Health aspects, Respiratory system agents -- Health aspects, COVID-19 -- Health aspects, General interest, News, opinion and commentary
Abstract

Byline: By, Nisha Mal A protein treatment that can be inhaled directly into the lungs has been shown to 'accelerate recovery' and reduce the odds of developing severe Covid-19 in [...]

Published
2020

206. Researchers at University of Utah Release New Data on Respiratory Medicine (Short-Term Elevation of Fine Particulate Matter Air Pollution and Acute Lower Respiratory Infection)

Subjects
Drug therapy, Health aspects, Air quality -- Health aspects, Physical fitness -- Health aspects, Air pollution -- Health aspects, Respiratory system agents -- Health aspects, Air pollution control -- Health aspects, Lung diseases -- Drug therapy -- Health aspects
Abstract

2018 OCT 13 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Current study results on Health and Medicine - Respiratory Medicine have been [...]

Published
2018

207. Researchers at University Francois Rabelais of Tours Target Respiratory Tract Diseases and Conditions (Therapeutic antibodies: A new era in the treatment of respiratory diseases?)

Subjects
Drug therapy, Health aspects, Mortality -- France, Lung cancer -- Drug therapy -- Health aspects, Physical fitness -- Health aspects, Respiratory system agents -- Health aspects, Biopharmaceuticals -- Health aspects, Antibodies -- Health aspects
Abstract

2018 SEP 22 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Fresh data on Respiratory Tract Diseases and Conditions are presented in a [...]

Published
2018

208. Findings from Inonu University Update Understanding of Adrenergic Bronchodilators (Protective and therapeutic effects of dexpanthenol on isoproterenol-induced cardiac damage in rats)

Subjects
Health aspects, Physical fitness -- Health aspects, Respiratory system agents -- Health aspects
Abstract

2018 JUN 9 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Current study results on Drugs and Therapies - Adrenergic Bronchodilators have been [...]

Published
2018

209. Studies from National Institute of Environmental Health Sciences Update Current Data on Mammal Research (Inter-individual variation in health and disease associated with pulmonary infectious agents)

Subjects
United States. National Institute of Environmental Health Sciences, Health aspects, Physical fitness -- Health aspects, Diseases -- North Carolina -- Health aspects, Heart diseases -- Health aspects, Respiratory system agents -- Health aspects, Environmental health -- Health aspects
Abstract

2018 APR 14 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Research findings on Life Science Research - Mammal Research are discussed in [...]

Published
2018

210. New nasal spray treats Delta variant infection in mice, indicating broad spectrum results

Subjects
Cornell University, University of British Columbia, Health aspects, Vaccines -- Health aspects, Respiratory system agents -- Health aspects, COVID-19 -- Health aspects, Respiratory agents -- Health aspects
Abstract

2022 APR 13 (NewsRx) -- By a News Reporter-Staff News Editor at Vaccine Weekly -- Researchers have shown a new compound delivered in a nasal spray is highly effective in [...]

Published
2022

211. Studies from State University of New York (SUNY) Stony Brook Have Provided New Information about Aerosol Medicine and Pulmonary Drug Delivery (The Unfulfilled Promise of Inhaled Therapy In Ventilator-associated Infections: Where Do We Go From ...)

Subjects
State University of New York, Care and treatment, Health aspects, Drug delivery systems -- Health aspects, Antibiotics -- Health aspects, Respiratory system agents -- Health aspects, Infection -- Care and treatment, Methicillin -- Health aspects, Drugs -- Vehicles, Respiratory agents -- Health aspects
Abstract

2022 APR 1 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- Researchers detail new data in Drugs and Therapies - Aerosol Medicine and Pulmonary [...]

Published
2022

212. Therapeutic focus: respiratory

Author

Knutsen, Rebecca Mayer

Subjects
AstraZeneca PLC, Combivent (Medication), Ventolin (Medication), ProAir HFA (Medication), Budesonide (Medication), Xolair (Medication), Advair Diskus (Medication), Symbicort (Medication), Flovent (Medication), Spiriva (Medication), QVAR (Medication), Health aspects, Respiratory system agents -- Health aspects, Pharmaceutical industry -- Health aspects, Asthma -- Health aspects, Respiratory agents -- Health aspects
Abstract

Recently plagued by patent expirations and generic competition, the respiratory space has found new energy through innovative beyond-the-pill partnerships. Indeed, an enhanced understanding of disease drivers continues to breathe new [...]

Published
2016

213. Therapeutic focus: rare diseases

Author

Knutsen, Rebecca Mayer

Subjects
Advate (Medication) -- Prices and rates, Avonex (Medication) -- Prices and rates, Revlimid (Medication) -- Prices and rates, Soliris (Medication) -- Prices and rates, Rituxan (Medication) -- Prices and rates, Rebif (Medication) -- Prices and rates, Alimta (Medication) -- Prices and rates, Tasigna (Medication) -- Prices and rates, Gleevec (Medication) -- Prices and rates, Copaxone (Medication) -- Prices and rates, Prices and rates, Officials and employees, Health aspects, Company pricing policy, Respiratory system agents -- Health aspects, Drug approval -- Health aspects, Respiratory agents -- Health aspects
Abstract

The grand secret of the rare-disease space? That rare diseases aren't really that rare, with around one in ten Americans afflicted. But with drugs treating these conditions priced at sky-high [...]

Published
2016

214. Ena starts phase 1 trial of COVID-19-preventing nasal spray

Author

Taylor, Nick Paul

Subjects
Health aspects, Product development, Clinical trials -- Health aspects, Respiratory system agents -- Health aspects, Medical research -- Health aspects, Virus diseases -- Health aspects, COVID-19 -- Health aspects, Medicine, Experimental -- Health aspects, Respiratory agents -- Health aspects
Published
2021

215. Leiden Medical Center and Intravacc to start clinical trial with new intranasal corona vaccine

Subjects
Health aspects, Research and development, Clinical trials -- Health aspects, Medical centers -- Health aspects, COVID-19 vaccines -- Health aspects, Respiratory system agents -- Health aspects, Medical research -- Health aspects, Industrial research -- Health aspects, Medicine, Experimental -- Health aspects, Respiratory agents -- Health aspects
Abstract

2022 JAN 19 (NewsRx) -- By a News Reporter-Staff News Editor at Vaccine Weekly -- Intravacc, a global leader in translational research and development of therapeutic vaccines and vaccines against [...]

Published
2022

216. Noninvasive ventilation for respiratory failure: a note of caution in selected patients

Author

Macharete, Caroline, Ventura, Lara, Rubio, Olga, Catalan, Ignacio, Cano, Silvia, Alcoverro, Josep-Maria, and Subira, Carles

Subjects
Care and treatment, Health aspects, Mortality, Respiratory insufficiency -- Care and treatment, Chronic obstructive lung disease -- Care and treatment, Respiratory system agents -- Health aspects, Respiratory agents -- Health aspects, Lung diseases, Obstructive -- Care and treatment
Abstract

Author(s): Caroline Macharete [sup.1], Lara Ventura [sup.1], Olga Rubio [sup.1], Ignacio Catalan [sup.1], Silvia Cano [sup.1], Josep-Maria Alcoverro [sup.1], Carles Subira [sup.1], Jaume Masclans [sup.1], Gina Rognoni [sup.1], Rafael Fernandez [...]

Published
2018
Full Text
View/download PDF

218. Investigators from Royal Brompton Hospital Release New Data on Chronic Obstructive Pulmonary Disease (Critical inhaler errors in asthma and COPD: a systematic review of impact on health outcomes)

Subjects
Drug therapy, Health aspects, Drug delivery systems -- Health aspects, Physical fitness -- Health aspects, Respiratory system agents -- Health aspects, Medical research -- Health aspects, Asthma -- Drug therapy -- Health aspects
Abstract

2018 FEB 17 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Researchers detail new data in Lung Diseases and Conditions - Chronic Obstructive [...]

Published
2018

219. Eureka Therapeutics Announces Successful Preclinical Results of InvisiMask Human Antibody Nasal Spray Against SARS-CoV-2 Infection

Subjects
Monoclonal antibodies -- Health aspects, Respiratory system agents -- Health aspects, Infection -- Health aspects, COVID-19 -- Health aspects, Business, international, Law
Abstract

Eureka Therapeutics, Inc. announced today successful preclinical results from its InvisiMask Human Antibody Nasal Spray in mice, which offers protection against SARS-CoV-2 S pseudotyped virus infection for up to 10 [...]

Published
2020

220. Eureka Therapeutics Announces Successful Preclinical Results of InvisiMask[TM] Human Antibody Nasal Spray Against SARS-CoV-2 Infection

Subjects
United States. Food and Drug Administration, Respiratory system agents -- Health aspects, Infection -- Health aspects, Antibodies -- Health aspects, COVID-19 -- Health aspects, Business, Business, international
Abstract

- Newly published study reports InvisiMask[TM], a self-administered nasal spray, protects against SARS-CoV-2 infection for up to 10 hours in mice - InvisiMask human antibody nasal spray is designed to [...]

Published
2020

221. Rapid Therapeutic Selects Clinical Research Center to Start Clinical Trials Using its Proprietary CBD and CBG Formulation

Subjects
Respiratory system agents -- Health aspects, Medical research -- Health aspects, Business, international, Law
Abstract

(GlobeNewswire) - Rapid Therapeutic Science Laboratories, Inc. (OTC: RTSL) an SEC fully-reporting, growth-oriented aerosol manufacturing and marketing company focused on employing FDA-approved Metered Dose Inhaler (MDI) technology to deliver cannabinoid [...]

Published
2020

222. AstraZeneca Says New Dosing Of Imfinzi Approved In US

Subjects
AstraZeneca PLC, Cancer treatment -- Health aspects, Respiratory system agents -- Health aspects, Pharmaceutical industry -- Health aspects, Drug approval -- Health aspects, Non-small cell lung cancer -- Health aspects, General interest, News, opinion and commentary, Imfinzi (Medication) -- Health aspects
Abstract

London: AstraZeneca PLC has issued the following press release: AstraZeneca PLC on Friday said Imfinzi has been approved in the US for an additional dosing option, a 1,500 milligram fixed [...]

Published
2020

223. Matinas BioPharma Awarded up to $3.75 Million from the Cystic Fibrosis Foundation to Support Development of Oral Amikacin (MAT2501) for the Treatment of NTM Infections in Cystic Fibrosis Patients

Subjects
Amikacin -- Health aspects, Cystic fibrosis -- Health aspects, Respiratory system agents -- Health aspects, Infection -- Health aspects, Biological products industry -- Health aspects, Banking, finance and accounting industries
Abstract

(GlobeNewswire) - Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on developing next generation therapeutics to advance standards of care in areas of significant unmet medical [...]

Published
2020

224. Matinas BioPharma Awarded up to $3.75 Million from the Cystic Fibrosis Foundation to Support Development of Oral Amikacin (MAT2501) for the Treatment of NTM Infections in Cystic Fibrosis Patients

Subjects
Amikacin -- Health aspects, Cystic fibrosis -- Health aspects, Respiratory system agents -- Health aspects, Infection -- Health aspects, Biological products industry -- Health aspects, Business, international, Law
Abstract

(GlobeNewswire) - Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on developing next generation therapeutics to advance standards of care in areas of significant unmet medical [...]

Published
2020

225. AstraZeneca Says New Dosing Of Imfinzi Approved In US

Subjects
AstraZeneca PLC, Cancer treatment -- Health aspects, Respiratory system agents -- Health aspects, Pharmaceutical industry -- Health aspects, Drug approval -- Health aspects, Non-small cell lung cancer -- Health aspects, Business, international, Law, Imfinzi (Medication) -- Health aspects
Abstract

AstraZeneca PLC on Friday said Imfinzi has been approved in the US for an additional dosing option, a 1,500 milligram fixed dose every four weeks. Imfinzi is used in the [...]

Published
2020

226. Revelation Biosciences Inc. Announces the Start of a Phase 1 Clinical Study for REVTx-99, an Experimental Treatment for Respiratory Viral Infection, Including COVID-19

Subjects
Clinical trials -- Health aspects, Therapeutics -- Product development, Respiratory system agents -- Health aspects, Infection -- Drug therapy, COVID-19 -- Drug therapy, General interest, News, opinion and commentary
Abstract

MENLO PARK: Revelation Biosciences Inc. has issued the following press release: Revelation Biosciences Inc. (Revelation), a clinical stage life sciences company focused on the development of immunologic-based therapies for the [...]

Published
2020

227. First COVID-19 patient dosed in Phase II trial of Quellor

Subjects
Clinical trials -- Health aspects, Tumor necrosis factor -- Health aspects, Respiratory system agents -- Health aspects, Virus diseases -- Care and treatment, COVID-19 -- Care and treatment, Business, international, Law
Abstract

INmune Bio has announced that the first patient has been dosed in a Phase II clinical trial evaluating Quellor for the treatment of pulmonary complications from COVID-19. According to the [...]

Published
2020

228. Revelation Biosciences Inc. Announces the Start of a Phase 1 Clinical Study for REVTx99, an Experimental Treatment for Respiratory Viral Infection, Including COVID19

Subjects
Clinical trials -- Health aspects, Therapeutics -- Product development, Respiratory system agents -- Health aspects, Infection -- Drug therapy, COVID-19 -- Drug therapy, Business, Business, international
Abstract

-First cohort fully enrolled and dosed- MENLO PARK, Calif. -- Revelation Biosciences Inc. (Revelation), a clinical stage life sciences company focused on the development of immunologic-based therapies for the prevention [...]

Published
2020

229. INmune Bio, Inc. Announces First Patient Dosed in Phase 2 Trial of Quellor for Pulmonary Complications in COVID-19 Patients

Subjects
Clinical trials -- Health aspects, Tumor necrosis factor -- Health aspects, Respiratory system agents -- Health aspects, Virus diseases -- Care and treatment, COVID-19 -- Care and treatment, Business, international, Law
Abstract

(GlobeNewswire) - INmune Bio, Inc. (NASDAQ: INMB) (the, Company), a clinical-stage immunology company focused on developing treatments that harness the patients innate immune system to fight disease, announced today that [...]

Published
2020

230. Researchers develop nasal spray to prevent Covid infections

Subjects
Vaccines -- Health aspects, Respiratory system agents -- Health aspects, Medical research -- Health aspects, Infection -- Prevention, COVID-19 -- Prevention, Business, international, Law, Columbia University
Abstract

Researchers from Columbia University have developed a long-lasting and affordable nasal spray that can successfully prevent Covid-19 infections. These sprays have currently been tested in ferrets, and 3D model of [...]

Published
2020

231. US FDA approved HWGB'S JV Partner, EBI to conduct Phase IV clinical trial for prevention of COVID-19

Subjects
United States. Food and Drug Administration, Clinical trials -- Health aspects, Vaccines -- Product development, Severe acute respiratory syndrome -- Drug therapy, Venture capital companies -- Joint ventures -- Product development, Respiratory system agents -- Health aspects, Drug approval -- Health aspects, COVID-19 -- Drug therapy, Company joint venture, Business, international, Law
Abstract

Ho Wah Genting Berhad's ('HWGB' or the 'Company') (Bursa Stock Code:9601) wholly-owned subsidiary, HWGB Biotech Sdn Bhd's ('HWGB Biotech') joint venture partner, US-based E-MO Biology Inc ('EBI'), has obtained approval [...]

Published
2020

232. CF Foundation Commits up to $14 Million in Funding to Expand Research Agreement With Synspira Therapeutics

Subjects
Cystic fibrosis -- Health aspects, Respiratory system agents -- Health aspects, Enzymes -- Health aspects, Research funding -- Health aspects, Business, international, Law
Abstract

Today, the Cystic Fibrosis Foundation announced it is expanding its research collaboration with Synspira Inc., committing up to $14 million in additional funding to develop a non-porcine enzyme replacement therapy [...]

Published
2020

233. Inhaled antibody drug for COVID-19 clears coronavirus in animals

Subjects
Coronaviruses -- Health aspects, B cells -- Health aspects, Monoclonal antibodies -- Health aspects, Hamsters -- Health aspects, Respiratory system agents -- Health aspects, Biopharmaceuticals -- Health aspects, COVID-19 -- Health aspects, Business, international, Law
Abstract

Monoclonal antibodies for COVID-19 recently took center stage as Regenerons experimental cocktail was used to treat President Donald Trump, who went on to rave about it. But that therapy, as [...]

Published
2020

234. Inhaled antibody treatment for COVID-19 shows success in pre-clinical trials

Subjects
Clinical trials -- Health aspects, Monoclonal antibodies -- Health aspects, Respiratory system agents -- Health aspects, COVID-19 -- Health aspects, Business, international, Law
Abstract

A highly neutralising monoclonal antibody (mAb), named AR-711, discovered from convalescent COVID-19 patients, has successfully eliminated all detectable SARS-CoV-2 virus in infected animals at substantially lower doses than injected COVID-19 [...]

Published
2020

235. Inhaled antibody drug for COVID-19 clears coronavirus in animals

Author

Liu, Angus

Subjects
Health aspects, Coronaviruses -- Health aspects, B cells -- Health aspects, Monoclonal antibodies -- Health aspects, Hamsters -- Health aspects, Respiratory system agents -- Health aspects, Biopharmaceuticals -- Health aspects, COVID-19 -- Health aspects
Published
2020

236. UT-Austin researchers develop potential treatment for COVID-19

Subjects
Coronaviruses -- Health aspects, Respiratory system agents -- Health aspects, COVID-19 -- Health aspects, Business, international, Law
Abstract

A team of UT researchers is developing an inhalable therapy for COVID-19, but the research needs further funding to go to clinical trials. Pharmacy professor Hugh Smyth said the treatment [...]

Published
2020

237. Oncocyte Receives Final Pricing Decision for DetermaRx Molecular Test for Lung Cancer from Centers for Medicare and Medicaid Services

Subjects
United States. Centers for Medicare and Medicaid Services, Lung cancer -- Care and treatment, Medicare -- Health aspects, Respiratory system agents -- Health aspects, Business, international, Law
Abstract

(GlobeNewswire) - Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, today announced that [...]

Published
2020

238. Live COVID-19 Updates: Kuwait's total caseload tops 92,000

Subjects
Vaccines -- Health aspects, Respiratory system agents -- Health aspects, COVID-19 -- Health aspects, Business, general, General interest, News, opinion and commentary, University of Hong Kong
Abstract

BEIJING, September 9, 2020 (Xinhua via COMTEX) -- The following are the updates on the global fight against the COVID-19 pandemic. - - - - KUWAIT CITY -- Kuwait on [...]

Published
2020

239. Oncocyte Receives Final Pricing Decision for DetermaRx(TM) Molecular Test for Lung Cancer from Centers for Medicare and Medicaid Services

Subjects
United States. Centers for Medicare and Medicaid Services, Medicare -- Health aspects, Respiratory system agents -- Health aspects, Non-small cell lung cancer -- Health aspects, Banking, finance and accounting industries, Business
Abstract

IRVINE, Calif., Sep 09, 2020 (GLOBE NEWSWIRE via COMTEX) -- Pricing in line with comparable high-value molecular tests for oncology indications Consistent growth in testing volumes now provides immediate and [...]

Published
2020

240. Morphic Announces that AbbVie Exercises License Option to v6 Integrin Inhibitor Program, Including MORF-720, for Fibrotic Diseases

Subjects
Chronic diseases -- Health aspects, Transforming growth factors -- Health aspects, Respiratory system agents -- Health aspects, Integrins -- Health aspects, Business, international, Law
Abstract

(GlobeNewswire) - Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, and AbbVie (NYSE: ABBV) today announced [...]

Published
2020

241. Morphic Announces that AbbVie Exercises License Option to I[+ or -]vB6 Integrin Inhibitor Program, Including MORF-720, for Fibrotic Diseases

Subjects
Chronic diseases -- Health aspects, Legal fees -- Health aspects, Respiratory system agents -- Health aspects, Integrins -- Health aspects, Banking, finance and accounting industries, Business
Abstract

WALTHAM, Mass., Aug 25, 2020 (GLOBE NEWSWIRE via COMTEX) -- AbbVie to pay Morphic license fee of $20 million, with future potential milestones and royalties AbbVie to lead further development [...]

Published
2020

242. SMHS researchers examine nitric oxide as potential COVID-19 treatment Women's basketball adds two former players as graduate assistants D.C. Council votes to advance plans to construct GW Hospital facility in Southeast Metro to increase train and bus serv

Author

Garcia, Tiffany

Subjects
Coronaviruses -- Health aspects, Medical students -- Planning -- Health aspects, Respiratory system agents -- Health aspects, Nitric oxide -- Health aspects -- Planning, Health facilities construction -- Health aspects -- Planning, Company business planning, News, opinion and commentary, Sports and fitness
Abstract

Byline: Tiffany Garcia School of Medicine and Health Sciences researchers found that nitric oxide could serve as a therapeutic to control the replication and spread of COVID-19, according to a [...]

Published
2020

243. UK company Synairgen declares clinical trial of protein treatment for Covid as successful

Subjects
Clinical trials -- Health aspects, Biological response modifiers -- Health aspects, Coronaviruses -- Health aspects, Respiratory system agents -- Health aspects, Virus diseases -- Health aspects, Interferon -- Product development, Business, international, Law
Abstract

A UK-based biotech company on Monday declared positive breakthrough results from a clinical trial of a protein-based treatment for COVID-19, which greatly reduced patients requiring intensive care. Synairgen said its [...]

Published
2020

244. CytoDyn Announces Execution of Exclusive Agreement with American Regent for Distribution and Supply of Leronlimab for Treatment of COVID-19 in United States

Subjects
United States. Food and Drug Administration, Respiratory system agents -- Health aspects, Drug approval -- Health aspects, COVID-19 -- Care and treatment, Banking, finance and accounting industries, Business
Abstract

VANCOUVER, Washington, Jul 06, 2020 (GLOBE NEWSWIRE via COMTEX) -- This Agreement will allow for immediate distribution of leronlimab to patients for the treatment of COVID-19 upon successful completion of [...]

Published
2020

245. CytoDyn Announces Execution of Exclusive Agreement with American Regent for Distribution and Supply of Leronlimab for Treatment of COVID-19 in United States

Subjects
United States. Food and Drug Administration, Respiratory system agents -- Health aspects, Drug approval -- Health aspects, COVID-19 -- Care and treatment, Banking, finance and accounting industries, Business
Abstract

VANCOUVER, Washington, Jul 03, 2020 (GLOBE NEWSWIRE via COMTEX) -- This Agreement will allow for immediate distribution of leronlimab to patients for the treatment of COVID-19 upon successful completion of [...]

Published
2020

246. BetterLife Pharma (OTCQB:BETRD) Believe Inhalation Device Containing Proprietary Interferon May Fight Off COVID-19

Subjects
Biological response modifiers -- Health aspects, Coronaviruses -- Health aspects, Respiratory system agents -- Health aspects, Medical research -- Health aspects, Interferon -- Health aspects, COVID-19 -- Care and treatment, Business, international, Law
Abstract

(GlobeNewswire) - BetterLife Pharma(OTCQB:BETRD) (CSE: BETR) (FRANKFURT: NPAT), an emerging clinical stage pharmaceutical development company, believe that a coronavirus inhaler therapeutic may hold the key to helping patients fight off [...]

Published
2020

247. BetterLife Pharma (OTCQB:BETRD) Believe Inhalation Device Containing Proprietary Interferon May Fight Off COVID-19

Subjects
Biological response modifiers -- Health aspects, Coronaviruses -- Health aspects, Respiratory system agents -- Health aspects, Medical research -- Health aspects, Interferon -- Health aspects, COVID-19 -- Care and treatment, Banking, finance and accounting industries, Business
Abstract

New York, June 30, Jun 30, 2020 (GLOBE NEWSWIRE via COMTEX) -- BetterLife Pharma (OTCQB:BETRD) (CSE: BETR) (FRANKFURT: NPAT), an emerging clinical stage pharmaceutical development company, believe that a coronavirus [...]

Published
2020

248. CytoDyn and NIH of Mexico Complete Memorandum of Understanding to Conduct Small Covid-19 Phase 3 Trial for Severe and Critically Ill Patients

Subjects
Clinical trials -- Health aspects, Respiratory system agents -- Health aspects, COVID-19 -- Health aspects, Business, international, Law
Abstract

(GlobeNewswire) - CytoDyn Inc. (OTC.QB: CYDY), (CytoDyn or the Company'), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today [...]

Published
2020

249. BetterLife Pharma (OTCQB:BETRF): How a Simple Inhaler May Fight Off COVID-19

Subjects
Coronaviruses -- Health aspects, Respiratory system agents -- Health aspects, Medical research -- Health aspects, COVID-19 -- Care and treatment, Banking, finance and accounting industries, Business
Abstract

New York City, June 29, Jun 29, 2020 (GLOBE NEWSWIRE via COMTEX) -- The emerging biotechnology company BetterLife Pharma (OTCQB: BETRF) (CSE: BETR) (FRANKFURT: NPAT) believe that a coronavirus inhaler [...]

Published
2020

250. CytoDyn and NIH of Mexico Complete Memorandum of Understanding to Conduct Small Covid-19 Phase 3 Trial for Severe and Critically Ill Patients

Subjects
Clinical trials -- Health aspects, Respiratory system agents -- Health aspects, COVID-19 -- Health aspects, Banking, finance and accounting industries, Business
Abstract

VANCOUVER, Washington, Jun 29, 2020 (GLOBE NEWSWIRE via COMTEX) -- CytoDyn Inc. (OTC.QB: CYDY), ('CytoDyn' or the 'Company'), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with [...]

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results